Evaluation of Early Response to Treatment of Hepatocellular Carcinoma with Yttrium-90 Radioembolization Using Quantitative Computed Tomography Analysis

Korean J Radiol. 2019 Mar;20(3):449-458. doi: 10.3348/kjr.2018.0469.

Abstract

Objective: To identify an imaging predictor for the assessment of early treatment response to yttrium-90 transarterial radioembolization (TARE) in patients with hepatocellular carcinoma (HCC), using a quantitative assessment of dynamic computed tomography (CT) images.

Materials and methods: Dynamic contrast-enhanced CT was obtained pre- and 4 weeks post-TARE in 44 patients (34 men, 10 women; mean age, 60 years) with HCC. Computer software was developed for measuring the percentage increase in the combined delayed-enhancing area and necrotic area (pD + N) and the percentage increase in the necrotic area (pNI) in the tumor-containing segments pre- and post-TARE. Local progression-free survival (PFS) was compared between patient groups using Cox regression and Kaplan-Meier analyses.

Results: Post-TARE HCC with pD + N ≥ 35.5% showed significantly longer PFS than those with pD + N < 35.5% (p = 0.001). The local tumor progression hazard ratio was 17.3 (p = 0.009) for pD + N < 35.5% versus pD + N ≥ 35.5% groups. HCCs with a high pNI tended to have longer PFS, although this difference did not reach statistical significance.

Conclusion: HCCs with a larger pD + N are less likely to develop local progression after TARE.

Keywords: Computed tomography; Hepatocellular carcinoma; Quantitative analysis; Response; Treatment outcome; Yttrium radioisotopes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular / diagnostic imaging
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / therapy*
  • Embolization, Therapeutic*
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Liver / diagnostic imaging
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / mortality
  • Liver Neoplasms / therapy*
  • Male
  • Middle Aged
  • Progression-Free Survival
  • Proportional Hazards Models
  • Radiopharmaceuticals / chemistry*
  • Tomography, X-Ray Computed*
  • Treatment Outcome
  • Yttrium Radioisotopes / chemistry

Substances

  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • Yttrium-90